Back to search results

LC106 for Bacterial Vaginosis

This study is testing a vaginal live biotherapeutic tablet called LC106, which contains six strains of L. crispatus bacteria. It's for women aged 18 to 40 who have bacterial vaginosis (an imbalance of bacteria in the vagina) and previously participated in the VIBRANT study, receiving the active treatment. The main goal is to see how consistently LC106 helps healthy bacteria colonize the vagina. You cannot join if you have an infection needing antibiotics, or have used antibiotics or probiotics recently. The study aims to enroll 71 participants, but its current recruitment status is unclear.

Study design
This is an open-label (you and the researchers know what treatment you receive), single-arm (everyone gets the same treatment) study involving about 71 participants.
What's involved
If your vaginal microbiome isn't Lactobacillus-predominant, you will receive LC106 in the clinic for three consecutive days.
Compensation
Not stated in the trial record.
Follow-up
The study measures colonization with LC106 isolates at 5 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07305844

Impact of Clinician-administered Vaginal Live Biotherapeutic Product

Completed
EARLY_PHASE1Ages 18–40InterventionalTreatment
Caroline Mitchell
~26 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:LC106

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of colonization with LBP isolates
Measured over 5 weeks

Conditions

Bacterial Vaginosis

Explore related trials

Bacterial Vaginosis

NCT07305844

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • CAPRISA

    Vulindlela, South Africano site contact published

  • Massachusetts General Hospital

    Boston, Massachusettsno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Caroline M Mitchell, MD, MPH · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
  • Disebo Potloane, MD · PRINCIPAL_INVESTIGATOR · Centre for the AIDS Programme of Research in South Africa

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Previous participant in the VIBRANT study, randomized to active LBP
Nugent score 4-10

Exclusion

Infection requiring antibiotics detected on screening labs
Use of oral or vaginal antibiotics in the 30 days prior to screening
Use of an oral or vaginal probiotic in the 30 days prior to screening

What this trial measures

  • Rate of colonization with LBP isolates5 weeks

    Detection of at least one isolate from the LBP with at least 5% relative abundance by metagenomics, or a combination of isolates at 10% or higher.